A single amino acid change (D8N) in the spider venom peptide Pn3a increased its potency at the pain channel NaV1.7 by 20-fold while maintaining selectivity and reducing pain in mice at lower doses.
20-fold potency increasePn3a[D8N] single mutation improved NaV1.7 inhibition while maintaining >100-fold channel selectivity
What the researchers found
The Pn3a[D8N] mutation increased NaV1.7 inhibition potency 20-fold while maintaining >100-fold selectivity over NaV1.4, NaV1.5, and NaV1.6, with confirmed analgesic activity at lower doses in vivo.
Why it matters
NaV1.7 is a validated pain target with strong human genetic evidence. Engineering more potent and selective peptide inhibitors brings us closer to non-opioid pain therapeutics.
The numbers in context
D8N: 20-fold potency; >100-fold selectivity over NaV1.4/1.5/1.6; 3-fold lower dose in vivo; K22/K24 essential; Y4/Y27/W30 >250-fold loss
How the study worked
Rational peptide engineering with 17 Pn3a analogues tested via patch-clamp electrophysiology, molecular modeling of channel interactions, and in-vivo postsurgical pain model in mice.
Who was studied
17 Pn3a analogues tested at hNaV1.7; Pn3a[D8N] tested in mouse post-surgical pain model
What this study cannot tell us
Mouse pain model — human translation needed; peptide delivery challenges for clinical use; long-term safety not assessed; D8N improvement is still preclinical.
How to read the evidence
Strong structure-activity data with 17 analogues, validated by in-vivo pain model showing functional improvement — rigorous preclinical evidence.
When this study was published
Published in 2020; NaV1.7-targeted peptide analgesics remain an active area of non-opioid pain drug development.
The bigger picture
This work advances the development of peptide-based pain drugs that could offer alternatives to opioids, using venom-derived scaffolds refined through rational engineering.
Questions still open
- Can Pn3a[D8N] be formulated for practical clinical delivery?
- Would further engineering yield even more potent NaV1.7-selective analgesics?
- How does Pn3a compare to small-molecule NaV1.7 inhibitors in development?
Common questions
Can spider venom treat pain?
What is NaV1.7 and why target it?
Read the original research
Mapping the Molecular Surface of the Analgesic NaV1.7-Selective Peptide Pn3a Reveals Residues Essential for Membrane and Channel Interactions.
ACS pharmacology & translational science, 3(3), 535-546
Citation
Mueller, Alexander; Dekan, Zoltan; Kaas, Quentin; Agwa, Akello J; Starobova, Hana; Alewood, Paul F; Schroeder, Christina I; Mobli, Mehdi; Deuis, Jennifer R; Vetter, Irina. (2020). Mapping the Molecular Surface of the Analgesic NaV1.7-Selective Peptide Pn3a Reveals Residues Essential for Membrane and Channel Interactions.. ACS pharmacology & translational science, 3(3), 535-546. https://doi.org/10.1021/acsptsci.0c00002